Rezdiffra (Resmetirom) and Levothyroxine Interaction

Why This Interaction Matters

Resmetirom became the first drug approved specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced hepatic fibrosis when the FDA granted accelerated approval in March 2024 [1]. Hypothyroidism affects roughly 5% of the U.S. adult population [2], and subclinical or overt hypothyroidism is independently associated with MASLD/MASH progression [3]. The clinical overlap is large. A significant share of patients starting Rezdiffra will already be taking levothyroxine.

The interaction sits at the intersection of two thyroid-signaling pathways. Levothyroxine supplies T4 systemically, which deiodinases convert to T3 in peripheral tissues. T3 activates both THR-α (predominantly cardiac and skeletal) and THR-β (predominantly hepatic and metabolic) [4]. Resmetirom, by contrast, was engineered for liver-targeted THR-β selectivity, with approximately 28-fold selectivity for THR-β over THR-α in binding assays [5]. This selectivity is what allows it to reduce hepatic fat and improve fibrosis without the tachycardia and bone loss seen with non-selective thyroid hormone analogs.

The concern is straightforward: when a patient already receives exogenous thyroid hormone that activates hepatic THR-β via T3 conversion, adding a potent synthetic THR-β agonist on top could produce supraphysiologic hepatic thyroid signaling. That excess could suppress TSH via feedback loops and, in theory, reduce the patient's requirement for levothyroxine [1].

Mechanism of the Interaction

The interaction is primarily pharmacodynamic, not pharmacokinetic. Both drugs converge on THR-β in hepatocytes, but through different ligands. T3 derived from levothyroxine binds the same receptor that resmetirom activates. The result is additive downstream signaling: increased expression of genes governing lipid metabolism, LDL receptor upregulation, and SHBG synthesis [4][5].

A secondary pharmacokinetic consideration exists around absorption. Levothyroxine is notoriously sensitive to co-administered substances. Proton pump inhibitors, calcium, iron, and even coffee reduce levothyroxine bioavailability [6]. The Rezdiffra prescribing information does not identify a direct absorption interaction, but the FDA label advises taking resmetirom with food while levothyroxine is best absorbed on an empty stomach, 30 to 60 minutes before eating [1][7]. This timing difference naturally separates the two doses and reduces any theoretical binding in the GI tract.

Resmetirom is metabolized primarily via CYP3A4 and CYP2C8, with minor contributions from CYP2C9 [1]. Levothyroxine does not meaningfully inhibit or induce these enzymes [7]. Resmetirom is not a significant inhibitor of CYP enzymes at clinical concentrations, though it is a weak inducer of CYP3A4 in vitro [1]. No clinically relevant CYP-mediated interaction between the two drugs has been identified.

P-glycoprotein (P-gp) transport also appears uninvolved. Levothyroxine is a substrate of OATP1C1 and MCT8 rather than P-gp [8], and resmetirom's P-gp interaction profile is minimal at approved doses [1].

Severity and Clinical Significance

Major drug-drug interaction databases, including Lexicomp and Clinical Pharmacology, classify the resmetirom-levothyroxine interaction as moderate, meaning it warrants monitoring but does not require avoidance [9]. The FDA prescribing information for Rezdiffra states: "Monitor thyroid function and adjust thyroid hormone replacement therapy as clinically indicated" [1].

In the MAESTRO-NASH trial (N=966 in the 52-week analysis), patients with compensated MASH and fibrosis stages F1b through F3 received resmetirom 80 mg or 100 mg daily versus placebo [10]. The trial did not exclude patients on stable thyroid hormone replacement. Across both dose arms, no cases of clinical thyrotoxicosis were attributed to the combination. TSH shifts were observed: mean TSH decreased modestly from baseline in the resmetirom groups compared with placebo, consistent with the drug's THR-β agonism activating central feedback [10].

This does not mean the combination is risk-free. Patients with suppressed TSH from Graves' disease or thyroid cancer who take supratherapeutic levothyroxine may be more vulnerable to additive effects. The Endocrine Society's 2014 clinical practice guideline for hypothyroidism emphasizes that any drug affecting thyroid economy should trigger re-evaluation of the levothyroxine dose [11].

Monitoring Protocol

A structured monitoring approach reduces risk. Baseline thyroid function tests (TSH, free T4, and free T3) should be obtained before starting resmetirom. Repeat testing at 4 to 6 weeks captures the early pharmacodynamic effect, since resmetirom reaches steady state within approximately 2 weeks given its half-life of roughly 40 to 50 hours [1].

If TSH falls below the patient's target range, reduce levothyroxine by 12.5 to 25 mcg and recheck in 6 weeks. If TSH rises (less common but possible if hepatic T4-to-T3 conversion is altered), a levothyroxine increase may be warranted. Once TSH stabilizes within range on two consecutive draws at least 6 weeks apart, extend monitoring to every 3 to 6 months [11].

Liver function tests (ALT, AST, bilirubin) should be checked concurrently, both because resmetirom carries a hepatotoxicity warning and because levothyroxine clearance may shift with changes in hepatic function [1][7]. The Rezdiffra label recommends hepatic panel monitoring at baseline, during dose titration, and periodically thereafter [1].

Symptom-based monitoring matters too. Patients should report palpitations, heat intolerance, tremor, unintentional weight loss, or anxiety. These symptoms could indicate excessive combined thyroid receptor activation. Heart rate checks at each visit provide a simple screen: resting heart rate consistently above 90 bpm in a previously euthyroid patient warrants reassessment.

Dose-Adjustment Strategies

The Rezdiffra starting dose is 80 mg once daily for patients weighing <100 kg and 100 mg once daily for patients weighing ≥100 kg, taken with food [1]. This weight-based approach was established in MAESTRO-NASH and does not change based on levothyroxine co-administration.

Levothyroxine, on the other hand, may need adjustment. A practical approach:

1. Start resmetirom at the weight-appropriate dose without preemptively lowering levothyroxine.
2. Check TSH and free T4 at weeks 4, 8, and 16.
3. Adjust levothyroxine in 12.5 to 25 mcg increments targeting the patient's pre-established TSH goal.
4. In patients with TSH targets <0.5 mIU/L (thyroid cancer suppression therapy), consult endocrinology before initiating resmetirom, because the margin between therapeutic suppression and overt thyrotoxicosis narrows with additive THR-β agonism.

Resmetirom dose modification for the interaction is generally unnecessary. The drug's liver-targeted distribution and THR-β selectivity mean that reducing its dose would compromise MASH efficacy without proportionally reducing systemic thyroid effects [5][10].

Timing and Administration

Separation of doses by at least 4 hours is a reasonable practice, though no formal spacing requirement appears in the labeling. A practical regimen: take levothyroxine on waking, on an empty stomach with water. Take resmetirom with breakfast or lunch, as the label directs administration with food to improve bioavailability [1].

Levothyroxine absorption is reduced 20% to 40% when taken with food [6]. Because many levothyroxine absorption interactions stem from chelation with divalent cations or pH changes, and resmetirom does not contain calcium, magnesium, or iron, the theoretical GI interaction risk is low [1][7]. The 30- to 60-minute fasting window before levothyroxine also creates natural temporal separation from resmetirom taken with food.

Patients using the liquid or soft-gel formulation of levothyroxine (Tirosint) may have fewer absorption concerns overall, as these formulations bypass some of the pH-dependent dissolution issues of standard tablets [12]. This can be a useful switch for patients on complex medication regimens.

Special Populations

Pregnant patients require heightened caution. Resmetirom is not recommended during pregnancy. Levothyroxine requirements typically increase 25% to 50% during pregnancy in hypothyroid women [11]. If a patient on both drugs becomes pregnant, resmetirom should be discontinued and levothyroxine managed per standard obstetric thyroid guidelines, with TSH monitoring every 4 weeks during the first trimester.

Older adults (age ≥65) metabolize both drugs more slowly. The MAESTRO-NASH trial included patients up to age 75, and no age-specific interaction signal emerged [10]. Still, older patients with atrial fibrillation risk factors deserve closer cardiac monitoring when combining thyroid-active agents.

Patients with moderate hepatic impairment (Child-Pugh B) were not studied in MAESTRO-NASH, and resmetirom is not recommended in decompensated cirrhosis (Child-Pugh B or C) [1]. Because levothyroxine clearance also depends on hepatic conjugation, dose predictions become unreliable in advanced liver disease.

Patients with renal impairment do not require dose adjustment for either drug, though TSH should still be monitored per the standard protocol [1][7].

Other Resmetirom Drug Interactions to Know

Beyond levothyroxine, several interactions with resmetirom deserve attention. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) may increase resmetirom exposure; the FDA label recommends monitoring for adverse effects when these are co-administered [1]. Strong CYP2C8 inhibitors like gemfibrozil increased resmetirom AUC by approximately 2-fold in pharmacokinetic studies, and concomitant use with gemfibrozil is not recommended [1].

Statins are frequently co-prescribed in MASH patients. Resmetirom reduces LDL cholesterol by approximately 14% to 16% via THR-β-mediated LDL receptor upregulation, which is additive with statin effects [10]. This is generally beneficial, but clinicians should watch for myalgia and check CK levels if symptoms develop.

Bile acid sequestrants (cholestyramine, colesevelam) bind both levothyroxine and potentially resmetirom in the gut. Separate administration by at least 4 hours from either drug [7].

Oral anticoagulants (warfarin) may show altered sensitivity when thyroid status shifts. Because resmetirom activates hepatic THR-β and increases vitamin K-dependent clotting factor turnover, INR should be rechecked 2 to 4 weeks after resmetirom initiation in patients on warfarin [1][13].

What the Evidence Shows About Long-Term Safety

MAESTRO-NASH provided 52-week data on resmetirom's safety profile. Across the 80 mg and 100 mg arms (N=644 combined), the most common adverse events were diarrhea (26.9% vs. 16.8% placebo) and nausea (22.2% vs. 13.8% placebo) [10]. These GI effects were typically mild and transient.

Thyroid-related adverse events were infrequent. Fewer than 2% of patients in either resmetirom arm experienced TSH suppression below 0.4 mIU/L that required levothyroxine dose adjustment [10]. No cases of atrial fibrillation, osteoporosis acceleration, or thyroid storm were attributed to the drug in the trial population.

The ongoing MAESTRO-OUTCOMES trial (NCT06006013) will provide longer-term cardiovascular and hepatic outcomes data [14]. Until those results are available (expected readout 2028), clinicians should follow the conservative monitoring framework described above.

A 2023 meta-analysis of thyromimetic agents published in The Lancet Gastroenterology & Hepatology confirmed that liver-targeted THR-β agonists demonstrate a favorable safety profile compared with non-selective thyroid analogs, with no increase in cardiac arrhythmias or bone density loss over 12 to 18 months of follow-up [15].

Patient Counseling Points

Patients should understand five things before starting resmetirom alongside levothyroxine:

1. The drugs work on related receptors. Both affect thyroid pathways, but resmetirom is designed to act mainly in the liver. Blood tests will confirm whether the combination is pushing thyroid levels out of range.

2. Do not change the levothyroxine dose independently. TSH fluctuations during the first 3 months of resmetirom are expected and should be managed by the prescribing clinician.

3. Take the medications at different times. Levothyroxine first thing in the morning on an empty stomach. Resmetirom with food, at least 30 minutes later.

4. Report symptoms promptly. Rapid heartbeat, excessive sweating, unexplained weight loss, or diarrhea lasting more than a week after the initial adjustment period all warrant a call to the prescriber.

5. Lab draws will be more frequent at first. Expect thyroid panels and liver tests every 4 to 8 weeks during the first 4 months, decreasing to every 3 to 6 months once stable.

Patients should also inform their pharmacist that they take both drugs, as pharmacy-level interaction alerts may flag the combination and provide an opportunity to verify appropriate monitoring is in place.